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Abstract
Background: Similarly to other tumor types, an imbalance between unrestrained cell proliferation and impaired
apoptosis appears to be a major unfavorable feature of hepatocellular carcinoma (HCC). The members of IAP family are
key regulators of apoptosis, cytokinesis and signal transduction. IAP survival action is antagonized by specific binding of
Smac/DIABLO and XAF1. This study aimed to investigate the gene and protein expression pattern of IAP family members
and their antagonists in a series of human HCCs and to assess their clinical significance.
Methods: Relative quantification of IAPs and their antagonist genes was assessed by quantitative Real Time RT-PCR
(qPCR) in 80 patients who underwent surgical resection for HCC. The expression ratios of XIAP/XAF1 and of XIAP/
Smac were also evaluated. Survivin, XIAP and XAF1 protein expression were investigated by immunohistochemistry.
Correlations between mRNA levels, protein expression and clinicopathological features were assessed. Follow-up data
were available for 69 HCC patients. The overall survival analysis was estimated according to the Kaplan-Meier method.
Results: Survivin and Livin/ML-IAP mRNAs were significantly over-expressed in cancer tissues compared to non-
neoplastic counterparts. Although Survivin immunoreactivity did not correlate with qPCR data, a significant relation was
found between higher Survivin mRNA level and tumor stage, tumor grade and vascular invasion.
The mRNA ratio XIAP/XAF1 was significantly higher in HCCs than in cirrhotic tissues. Moreover, high XIAP/XAF1 ratio
was an indicator of poor prognosis when overall survival was estimated and elevated XIAP immunoreactivity was
significantly associated with shorter survival.
Conclusion: Our study demonstrates that alterations in the expression of IAP family members, including Survivin and
Livin/ML-IAP, are frequent in HCCs. Of interest, we could determine that an imbalance in XIAP/XAF1 mRNA expression
levels correlated to overall patient survival, and that high XIAP immunoreactivity was a poor prognostic factor.
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Background
Hepatocellular carcinoma (HCC), one of the most com-
mon malignant tumors worldwide, can be managed with
surgical resection or transplantation in selected cases,
whereas advanced tumors responds poorly to currently
available medical therapies [1].
The understanding of the molecular pathways leading to
the development of HCC may provide important data to
develop new therapies. Similarly to other tumor types, an
imbalance between unrestrained cell proliferation and
impaired apoptosis appears to be a major unfavorable fea-
ture of HCC [2]. Recent studies have documented the
over-expression of anti-apoptotic factors such as the
inhibitors of apoptosis proteins (IAPs) in a variety of solid
tumors and cancer cell lines [3].
Eight human IAPs have been identified so far: NAIP
(BIRC1), c-IAP1 (BIRC2), c-IAP2 (BIRC3), X-linked IAP
(XIAP, BIRC4), Survivin (BIRC5), Apollon (BRUCE,
BIRC6), Livin/ML-IAP (BIRC7) and IAP-like protein 2
(BIRC8) [4]. The members of IAP family, defined by the
presence of a baculovirus IAP repeat (BIR) protein
domain, are key regulators of apoptosis, cytokinesis and
signal transduction [3].
In addition to BIR domains, some members of this family
as XIAP, c-IAP1, c-IAP2 and Livin/ML-IAP also have a
RING domain that allows these proteins to act as E3 ubiq-
uitin ligases [5]. The E3 ubiquitin ligase activity of the
IAPs is capable of promoting ubiquitination and proteas-
omal degradation of caspases, TRAF2 and several other
partners [4].
XIAP is unique among IAP proteins, because of its ability
to inhibit and directly bind to activated caspases. Through
its BIR2 domain with its N-terminal linker, XIAP binds to
the active site of effectors caspase-3 or -7 and prevents sub-
strate binding and subsequent catalysis [5]. On the other
hand the BIR3 domain sequestrates active caspase-9. Fur-
thermore, XIAP has been shown to promote nuclear factor
-B (NF-B) activation by enhancing the translocation of
NF-B from the cytoplasm into the nucleus, by increasing
the degradation of inhibitor B protein and through its
association with TAK1 kinase and its cofactor TAB1 [6].
The two main antagonists of IAP proteins are Smac/DIA-
BLO and XAF1, involved in the balance and regulation of
apoptotic stimuli. Smac/DIABLO is released from mito-
chondria together with cytochrome c after initiation of
intrinsic apoptotic cascade. Smac appears to function as a
general IAP inhibitor in that it is shown to bind to XIAP,
cIAP1, cIAP2, Survivin, Livin/ML-IAP and BRUCE [3].
Conversely, the nuclear protein XAF1 exclusively interacts
with XIAP, restraining this IAP anti-apoptotic action even
in healthy cells. The mechanism by which XAF1 antago-
nizes XIAP is not completely explained, although recent
studies showed that XAF1 is able to sequestrate XIAP from
the cytoplasm into the nucleus. Moreover, XAF1 expres-
sion is low or absent in several tumor cell lines [7].
Since XIAP, Smac/DIABLO and XAF1 are antagonistic reg-
ulators, it is reasonable to assume that their relative
expression ratios, rather than the expression of a single
regulator, determine susceptibility for apoptosis [8].
This study aimed to investigate the gene and protein
expression pattern of IAP family members and its antago-
nists in a series of human HCCs and to assess their clinical
and prognostic significance.
Methods
Patients
Tissue samples were collected from 80 patients with liver
cirrhosis who underwent surgical resection for HCC,
between 1997 and 2007, in two hospitals (Istituto Clinico
Humanitas and San Paolo Hospital, Milan). The study
was carried out with Local Ethical committee approval.
Patients included 62 men and 18 women (mean age: 67
years, range: 42–83). The number of patients positive for
HCV, HBV was 54 and 9, respectively. None of the
patients received chemotherapy, radiation and/or alco-
holization therapy before surgery. In each case, samples of
HCC and surrounding cirrhotic tissue were snap-frozen
into cryovial with 1 ml of RNAlater® and stored at -80°C.
Routinely Hematoxylin-Eosin-stained sections of HCCs
and surrounding tissue were reviewed by two pathologists
according to WHO (2000) and TNM (2002). The HCCs
were histologically graded as I-IV on the basis of cellular
atypia and architectural complexity, according to Edmon-
son. The evaluated clinicopathological features were: sex,
age at diagnosis, viral infection, tumour histological fea-
tures (histotype, stage, number and diameter of nodules,
presence of capsule, microvascular invasion, Edmonson's
grade of differentiation). These are summarized in table 1.
Clinical outcome data were available in 69 patients
(86%). The follow-up period ranged from 1 to 75 months
(average 34 months). At the last follow-up, 15 patients
were deceased for HCC disease, whereas 22 patients were
alive with HCC recurrence.
RNA extraction and Reverse Transcription
Samples were homogenized in 1 ml of TRIzol® reagent
(Invitrogen, Milan, Italy) with a tissue lyser (Qiagen).
Total RNA was purified according to the manufacturers'
protocol. Spectrophotometrical RNA quantification was
conducted by GeneQuant II (Pharmacia Biotech) at 260
nm. Total RNA was stored at -80°C until molecular inves-
tigation was performed. In reverse transcription reactions,BMC Cancer 2009, 9:125 http://www.biomedcentral.com/1471-2407/9/125
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1 μg of total RNA from each sample was used for cDNA
generation in a final reaction volume of 100 μl with High
Capacity cDNA Archive Kit (Applied Biosystems).
Real Time RT-PCR
qPCR reactions of target (n = 9) and housekeeping (HKG
n = 8) genes were performed using Assay-on-Demand™
chemistry in an ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems, Foster City, CA, USA). The
assay identification numbers of target and housekeeping
genes are as follow: Hs00244967_m1 (BIRC1),
Hs00357350_m1 (BIRC2), Hs00154109_m1 (BIRC3),
Hs00236913_m1 (XIAP), Hs00213882_m1 (XAF1),
Hs00153353_m1 (BIRC5), Hs00212288_m1 (BIRC6),
Hs00223384_m1 (BIRC7), Hs00219876_m1 (Smac/DIA-
BLO), Hs00609297_m1 (HMBS), Hs99999905_m1
(GADPH), Hs 99999907_m1 (β-2M), Hs00188166_m1
(SDHA), Hs00824723_m1 (UBC), Hs00427620_m1
(TBP), Hs99999909_m1 (HPRT1), Hs99999903_m1
(ACTβ). The BIRC5 assay is specific for its two splicing var-
iants: NM_001168.2 and NM_001012271.1 (Survivin
and Survivin2B, respectively). The BIRC7 assay recognizes
all splicing variants of this gene.
Instrument raw data (fluorescence) of all the samples
were converted in threshold cycles (Ct) by SDS 1.2 soft-
ware (Applied Biosystem, Foster City, CA, USA). Ct values
were then imported in Excel worksheet for relative quan-
tification (RQ).
For RQ calculation, the geometrical mean of the three
more stable HKGs (HMBS, β-2M and GAPDH, GeNorm
software) [9], was used as normalization factor.
The Fold Change (FC) was calculated, defined as the ratio
between averaged normalized expression level of targets
in neoplastic and corresponding non-neoplastic samples.
Normalized RQ were log2-transformed for statistical anal-
ysis.
The ratios of XIAP and its antagonists were calculated as
follows: first, for every patient, the ratio between normal-
ized expression level of XIAP and its antagonists both in
cancer and in cirrhotic tissue was calculated. Then the
average value of these single ratios for all cancerous and
cirrhotic samples, respectively, was calculated. Finally the
fold change ratios of XIAP/XAF1 and XIAP/Smac were cal-
culated.
Tissue Microarray (TMA) construction
Representative tissue blocks from surgical resection of 40
patients (all included in qPCR study) were chosen to con-
struct 2 TMA as previously described [10]. For each
patient, seven cylindrical tissue cores were included in the
TMA: three from carcinoma, two from cirrhotic tissue
close to the cancer (< 1 cm) and two cirrhotic tissues taken
at a distance of at least 3 cm from neoplastic lesion. From
each TMA block a 4 μm-thick section was cut, stained with
H&E and inspected for adequacy before immunohisto-
chemical studies.
Immunohistochemistry
Serial 4 μm-thick sections from each TMA block were
stained with a series of primary antibody: XIAP (clone 48,
BD Biosciences, San Jose, CA USA) 1:100; XAF1
(ab32023, Abcam, Cambridge, USA) 1:100; full-length
Survivin (NB 500-201, Novus Biologicals, Littleton, USA)
1:2000. Immunohistochemistry was performed using a
Dako immunostainer (Dako, Glostrup, Denmark) and
immunostaining was revealed by Dako EnVision™ Detec-
tion Kit with Peroxidase/DAB as chromogen. All slides
were counterstained with haematoxylin.
Immunohistochemical results were evaluated by two
pathologists blinded to clinical data. Intensity and per-
centage of positive cells were calculated by averaging out
replicate cores. The percentage of immunoreactive tumor
cells and cirrhotic liver cells was determined and assigned
to one of the following five categories: 0, (<5%); 1, (5%–
24%); 2, (25%–49%); 3, (50%–74%) and 4, (≥75%). The
intensity of immunostaining was scored as absent (0),
mild (1), moderate (2) and marked (3). The percentage of
positive cells and staining intensity were multiplied to
produce a weighted score for each case. Cases with
weighted score 0 were defined as negative; 1–6 as low
expressors and 7–12 as high expressors.
Table 1: Patients' information.
Patient's age ≤67 y: 34 >67 y: 46
Patient's sex male: 62 female: 18
Histotype mixed: 24 trabecular: 51 pseudoglandular: 5
Viral infection HCV: 54 HBV: 9 None: 17
Stage pT1: 36 pT2: 33 pT3: 9 pT4: 2
Edmonson grade I: 8 II: 35 III: 32 IV: 5
Capsule NO: 34 YES: 46
Vascular invasion NO: 58 YES: 22
N° nodule 1: 48 >1: 32
Nodule size (cm) ≤3: 38 >3: 42BMC Cancer 2009, 9:125 http://www.biomedcentral.com/1471-2407/9/125
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Statistical analysis
Statistical analysis was conducted for both sets of results:
those from qPCR and those relative to immunohisto-
chemical studies. For samples clustering (qPCR results),
log2-transformed data were imported in dChip software
(dChip 2006, DNA-Chip Analyzer available for free at
http://www.hsph.harvard.edu/~cli/complab/dchip). Rel-
ative abundance of each gene was standardized by soft-
ware pre-processing steps (subtracting its mean and
dividing the result by its standard deviation) and hierar-
chical clustering analysis was then performed. The 1-Rank
correlation was employed as distance metric and the Aver-
age as a linkage method.
The genes with a global FC exceeding 2 or lower than 0.5
were statistically analyzed by univariate statistics (paired t
test).
For statistical purposes tumors with Edmondson's grade I
and II, III and IV were categorized in "low" and "high"
grade subsets, respectively. HCCs staged pT3 and pT4
were merged in the same group. Correlations of gene and
protein expression with clinicopathological features (his-
totype, viral infection, stage, grade, vascular invasion,
perineoplastic capsule, number of nodules, and diameter
of nodules) were analyzed by ANOVA and by Chi-square,
respectively.
To investigate whether expression levels of each gene and
protein were associated to patient survival, HCC samples
were categorized in high or low expressor groups if the tar-
get level was above or below the median expression value,
respectively. For XIAP/XAF1 and XIAP/Smac mRNA ratios
correlation to patients' outcome, HCCs were categorized
in "low" and "high" groups if the ratio value was lower or
higher than 2, respectively.
Overall and disease-free survival curves of HCC patients
were plotted according to the Kaplan-Meier method using
the log-rank statistics to test for statistical significant dif-
ference of generated curves (GraphPad Prism version 4.00
for Windows, San Diego, California, USA, http://
www.graphpad.com). Data with a p value lower than a
threshold limit (p < 0.05) were considered significant.
Results
Unsupervised analysis of IAP family members and their 
antagonists distinguishes HCC from non-neoplastic 
samples
All investigated genes were expressed at detectable levels
(Ct <40) in all HCCs and corresponding non-neoplastic
samples. To explore whether HCC and non-neoplastic tis-
sue could be distinguished at molecular level by the
expression profile of IAPs and inhibitors, unsupervised
hierachical clustering (dChip) was performed. The major-
ity of HCC samples (K, n = 62, 88%, p < 0.0001 by Fisher's
exact test) clustered in the same branch of the dendrogram
clearly separated from matched non-neoplastic counter-
parts (N) (see Additional file 1).
Expression of IAPs and its antagonists in HCC
Survivin and Livin/ML-IAP mRNAs exhibited significant
overexpression in cancer tissue compared to non-neoplas-
tic tissue (FC = 6.86, p < 0.001 and FC = 2.33, p < 0.001,
respectively) (table 2). Only NAIP mRNA revealed a
slightly lower expression level in cancer tissue compared
to non-neoplastic tissue, although the fold change was
not significant (FC = 0.67). The expression of other genes
was comparable between cancer and non-neoplastic tis-
sue (FC between 0,91 and 1.15).
Expression values of XAF1 and Smac/DIABLO were com-
parable between HCCs and non-neoplastic tissues (FC =
0.88 and FC = 1.10 respectively).
XIAP/XAF1 ratio was significantly higher in tumor than in
non-neoplastic parenchyma (FC = 3.02, p < 0.001; table
2). On the contrary Smac/DIABLO expression did not
Table 2: IAPs, XAF1, Smac/DIABLO normalized mRNA level and ratios.
Non neoplasia Hepatocarcinoma Fold Change p value*
NAIP (BIRC1) 1,24 (0,01–2,6) 0,82 (0,0004–3,6) 0,67
c-IAP1 (BIRC2) 2,13 (0.06–5.5) 1,94 (0.01–5.8) 0,91
c-IAP2 (BIRC3) 1,23 (0.1–6.1) 1,21 (0.04–5.9) 0,99
XIAP (BIRC4) 0,86 (0.3–2.5) 0,99 (0.06–2.2) 1,15
Survivin (BIRC5) 0,03 (0.03–0.1) 0,20 (0.1–1.6) 6,86 1·10–6
Bruce (BIRC6) 1,36 (0.06–5.9) 1,36 (0.02–3.3) 1,00
Livin/ML-IAP (BIRC7) 0,13 (0.01–1.5) 0,31 (0.01–3.6) 2,33 6·10–3
XAF1 (BIRC4BP) 0,69 (0.1–2.4) 0,61 (0.07–3.9) 0,88
Smac/DIABLO 1,03 (0.4–2.1) 1,13 (0.4–3.6) 1,10
Ratio XIAP/XAF1 2,29 (0.3–12.9) 6,90 (0.2–47.0) 3,02 3·10–4
Ratio XIAP/Smac/DIABLO 0,92 (0.04–2.0) 1,00 (0.01–4.2) 1,09
* Student t-test.BMC Cancer 2009, 9:125 http://www.biomedcentral.com/1471-2407/9/125
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show any significant difference between HCC and non-
neoplastic liver (FC = 1.09).
IAPs gene expression and clinical pathological features
A significant correlation was found between high Survivin
mRNA level and high tumor stage (pT3 and pT4, p =
0.03), high tumor grade (III and IV, p = 0.01) and vascular
invasion (p = 0.001). Moreover, high c-IAP2 mRNA level
was found to be significantly correlated with absence of
perineoplastic capsule (p = 0.02) and high NAIP mRNA
level with pseudoglandular histotype (p = 0.03). Finally,
high mRNA levels of c-IAP1 and Smac/DIABLO genes
were significantly correlated with younger patient age (p =
0.03 and p = 0.009 respectively).
IAPs gene expression and prognosis
Livin/ML-IAP and Survivin overexpression showed no
correlation with disease outcome, although there was a
trend for shorter overall survival in patients with high Sur-
vivin expression (p = 0.09). Kaplan-Meyer analysis dem-
onstrated a significantly shorter overall survival in
patients with high XIAP/XAF1 ratio (p = 0.03) (figure 1).
IAPs immunoreactivity and prognosis
The gene expression profiles obtained suggested that Sur-
vivin, XIAP and XAF1 could be important in determining
clinical outcomes of HCC patients. To confirm this
hypothesis, we investigated Survivin, XIAP and XAF1 pro-
tein expression by immunohistochemistry on a tissue
microarray platform.
Survivin immunoreactivity was intense in the cytoplasm
of cirrhotic liver cells, whereas HCC cells generally
showed weak cytoplasmic staining (figure 2). Nuclear Sur-
vivin immunoreactivity was found only in five HCC
(12,5%). Survivin immunoreactivity was not associated
with any clinical variable: although samples of HCC with
high level of Survivin were correlated with a shorter over-
all survival, this trend did not reach statistical significance
(p = 0.39).
XIAP immunoreactivity was detected exclusively in cyto-
plasm of both neoplastic and non-neoplastic liver cells.
Most HCC (82,5%, n = 33) displayed XIAP immunoreac-
tivity, whereas 70% (n = 28) of cirrhotic liver tissue (dis-
tant from the tumor) expressed XIAP (table 3). Survival
analysis demonstrated a significantly shorter overall sur-
vival in patients with high XIAP expression (p = 0.03) (fig-
ure 3); no correlations with other clinicopathological
parameters were found.
XAF1 immunoreactivity was detected in the cytoplasm
and nucleus of neoplastic and cirrhotic liver cells (figure
3). More than fifty percent of the HCC and cirrhotic tis-
sues did not show XAF1 expression (table 3) and the
expression score of XAF1 was significantly lower than that
of XIAP. XAF1 immunoreactivity did not reveal any signif-
icant correlation with clinicopathological parameters and
survival.
Since qPCR results showed that XIAP/XAF1 ratio strongly
correlated with prognosis, we divided patients in four
groups for survival analysis, depending on the following
immunoreactivity patterns: group 1, XIAP low and XAF1
negative; group 2, XIAP low and XAF1 positive; group 3,
XIAP high and XAF1 negative and group 4, XIAP high and
XAF1 positive. Interestingly, groups 3 and 4 showed a
trend for worse disease free and overall survival, although
it did not reach statistical significance (p = 0,10 and p =
0,08 respectively) (data not shown).
Discussion
This study is the first comprehensive evaluation of the
gene expression of all IAP family members in a large
number of human HCCs and paired cirrhotic paren-
chyma.
Our group and others have previously reported that Sur-
vivin is overexpressed in HCC [11,12]. Because of the sig-
nificant homology among IAP genes, it has been
hypothesized that other IAPs in addition to Survivin
could be important in HCC pathobiology.
The results of this study show that both Survivin and
Livin/ML-IAP mRNAs are overexpressed in HCC,
although the expression levels of these two genes are not
significantly associated with patient's survival. Survivin
overexpression is related with clinicopathological factors,
High XIAP/XAF1 ratio is a poor prognostic factor in HCC  patients Figure 1
High XIAP/XAF1 ratio is a poor prognostic factor in 
HCC patients. Kaplan-Meier survival curves of HCC 
patients characterized by XIAP/XAF1 mRNA ratio > 2 (high, 
solid line) or ≤ 2 (low, dashed line) when compared by log-
rank test. Overall survival was significantly different among 
the two subgroups of patients (p = 0.03).BMC Cancer 2009, 9:125 http://www.biomedcentral.com/1471-2407/9/125
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as high tumor grade, vascular invasion and higher tumor
stage (pT3 and pT4) in accordance with previous literature
[11,12]. However, the immunohistochemical analysis
showed a reduced Survivin expression in HCC compared
with the paired cirrhotic tissue and only a minority of
HCC cores displayed nuclear Survivin immunoreactivity.
This observation confirms the data reported by Chau et al.
[13]. In addition these authors confirmed by western blot-
ting analysis that Survivin protein was more abundant in
non-tumor liver tissues than in HCC samples [13].
Takashima et al. reported that the level of Survivin mRNA
increases along with the progression of chronic liver
injury, suggesting that Survivin may be an essential factor
Protein expression pattern of Survivin, XIAP and XAF1 in HCC tissues and non-neoplastic liver parenchyma Figure 2
Protein expression pattern of Survivin, XIAP and XAF1 in HCC tissues and non-neoplastic liver parenchyma. 
IAP members immunoreactivity was estimated by tissue microarray in a subset of HCC patients (n = 40). A-D, Representative 
Survivin cytoplasmatic immunostaining in a tumor core (A), in a tumor proximal to cirrhosis (C, N: cirrhosis, K: HCC), and in 
adjacent and long-distance non-neoplastic parenchyma (B and D, respectively). XIAP marked (score 12) and moderate (score 
8) immunoreactivity is shown for HCC (E and I, respectively) as well as for cirrhosis (F and L, respectively). G and H, Nuclear 
XAF1 staining is shown for tumor and non-neoplastic liver whereas XAF1 cytoplasmatic expression in HCC and cirrhosis is 
shown in panels M and N, respectively. Original magnification ×50 and ×250, for tissue cores and insets, respectively.BMC Cancer 2009, 9:125 http://www.biomedcentral.com/1471-2407/9/125
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in the survival of hepatocytes [14]. Recently, p53 dysfunc-
tion and hepatitis B virus infection have been shown to
regulate the expression of Survivin in HCC cells [15].
The prognostic role of Survivin in HCC is still unclear:
some studies support its correlation with poor prognosis
whereas other reports do not [16,17]. This discrepancy
may be explained with the multifunctional role of Sur-
vivin, as cell cycle and apoptosis-related protein [18].
Moreover, in response to cell-death stimuli, Survivin
directly interacts with XIAP by conserved BIR domain,
increasing XIAP stability, and indirectly sequesters Smac/
DIABLO away from XIAP [19].
Importantly, four Survivin isoforms (Survivin, Survivin-
2B, Survivin-ΔEx3 and Survivin-3B) have been described.
Recent transfection experiments documented different
roles for Survivin isoforms: Survivin-ΔEx3 retains the
same anti-apoptotic properties of Survivin, whereas Sur-
vivin-2B shows markedly reduced anti-apoptotic proper-
ties. Moreover different Survivin isoforms show opposite
roles in disease relapse and tumor cell survival in non-
small-cell lung cancer (NSCLC) [20]. Post-transcriptional
regulatory mechanisms have been described and may play
a role in regulating Survivin expression, causing discrep-
ancies between Survivin mRNA and Survivin immunore-
activity. Indeed these mechanisms include rapid changes
in Survivin protein stability modulated by phosphoryla-
tion [21], subcellular trafficking controlled by monoubiq-
uitination [22] and dynamic exchange of Survivin pools
among individual subcellular compartments [23].
Livin/ML-IAP mRNA has been found overexpressed in
some tumors including melanoma, breast, cervical, colon
and prostate cancers, as well in leukemia, in lymphoma
and in hepatoma cell lines. It has been proposed that
endogenous Livin/ML-IAP has a minor direct effect on
caspase activity whereas its anti-apoptotic effect could be
ascribed to its antagonizing activity on the XIAP-Smac/
DIABLO interaction. Moreover, researchers have shown
that only overexpression of Livin-α isoform is correlated
with high risk of relapse in bladder cancer [24]. To better
understand the role of Livin/ML-IAP in liver carcinogene-
sis, future research needs to investigate the expression and
localization of the protein and on the relationship
between Livin/ML-IAP α and β isoforms in HCC.
In this study we observed NAIP mRNA to be under
expressed in HCC compared to non-neoplastic liver
parenchyma, though not at a significant level. It must be
noted, however, that NAIP is highly expressed in macro-
phages [25] and therefore its expression by Kupffer cells,
Table 3: Survivin, XIAP and XAF1 immunoreactivity.
Survivin XIAP XAF1
I H C  s c o r e * n( % ) n( % ) n( % )
HCC Negative - 7 17,5% 23 57,5%
Low 22 55,0% 23 57,5% 17 42,5%
High 18 45,0% 10 25,0% -
Adjacent liver# Negative - 10 25,0% 21 52,5%
Low 2 5,0% 19 47,5% 19 47,5%
High 38 95,0% 11 27,5% -
Non-adjacent liver# Negative - 12 30,0% 25 62,5%
Low 1 2,5% 18 45,0% 15 37,5%
High 39 97,5% 10 25,0% -
The number (n) and the percentage of patients (%) in each IHC category are indicated.
*Negative (score 0), Low (score 1–6) and High (score 7–12).
#Adjacent liver: liver parenchyma at less than 1 cm from the tumor; non-adjacent liver: liver parenchyma at more than 3 cm from tumor.
High XIAP expression is a poor prognostic factor in HCC  patients Figure 3
High XIAP expression is a poor prognostic factor in 
HCC patients. Kaplan-Meier survival curves of HCC 
patients characterized by high XIAP expression (solid line) or 
low (dashed line) when compared by log-rank test. Overall 
survival was significantly different among the two subgroups 
of patients (p = 0.03).BMC Cancer 2009, 9:125 http://www.biomedcentral.com/1471-2407/9/125
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which are abundant in non neoplastic liver tissue, may
account for this result.
Although overexpression of c-IAP1, c-IAP2 in renal cell
carcinoma and in hepatoma cell line expressing hepatitis
B virus has been reported [26,27], and Apollon upregula-
tion was associated to chemoresistance in vitro and with
unfavorable clinical features at diagnosis [28,29], our
results showed that the gene expression levels of these IAP
members were similar in HCC and liver parenchyma.
Increased XIAP has been reported in a variety of human
tumors, including oesophageal carcinoma, clear cell renal
carcinoma, ovarian carcinoma, and lymphoma [30]. In
hepatocellular carcinoma XIAP overexpression compared
to non-cancerous tissues is equivocal [31,32], though
XIAP expression correlated with HCC recurrence and
patient survival after treatment [30]. We could correlate
high levels of XIAP immunoreactivity with decreased sur-
vival time in our series of HCC patients.
Apoptosis is controlled by the balance of antiapoptotic (as
IAPs) and pro-apoptotic regulators, as XAF1 and Smac/
DIABLO. These proteins are direct partners and inhibitors
of XIAP [5]. The down regulation of XAF1 and/or Smac/
DIABLO has been confirmed in a variety of cancer cells
and tumor tissues [32,33]. The analyses conducted in this
study show that the expression levels of XAF1 are similar
in HCC and cirrhotic tissue, either in terms of mRNA
expression or in terms of protein expression, as previously
reported [31]. The mRNA levels of Smac/DIABLO did not
varied significantly in our series of HCCs and matched
non-neoplastic counterparts [34].
Recent observations indicate a tight regulation of all com-
ponents and suggest that the relative expression ratio of
these antagonistic regulators, rather than the expression of
a single factor, determines susceptibility for apoptosis.
Studies have reported that the balance between XIAP and
Smac/DIABLO expression is gradually disturbed during
progression of renal cell carcinomas and testicular germ
cell tumors [19,35]. Similarly it was shown that the
expression ratio of XIAP and XAF1 determines resistance
or sensitivity of motoneurons to apoptosis [36]. Moreo-
ver, in gastric adenocarcinomas, the expression ratio
between XIAP and XAF1 increases [8] and the expression
balance of XIAP and XAF1 is an independent prognostic
factor [37].
This study demonstrates that the expression ratio between
XIAP and proapoptotic XAF1 is significantly higher in
HCC, whereas the ratio between XIAP and Smac/DIABLO
is comparable in neoplastic and non-neoplastic tissue.
Moreover the imbalance between XIAP and XAF1 expres-
sion strongly correlate with poor prognosis. This result
was confirmed when relative protein levels were consid-
ered, and patients with XIAP-positive/XAF1-negative
expression pattern showed a trend towards worse overall
and disease-free survival.
Therefore the imbalances between anti- and pro-apoptotic
factors may result in an increased effect of XIAP, thereby
generating an important selective survival advantage of
HCC cells. The inappropriate increase of antiapoptotic
XIAP over proapoptotic XAF1 in HCC may also contribute
to the well-known clinical resistance to anticancer drugs.
Conclusion
This study shows that alterations in the expression of IAP
family members, as well as a marked imbalance of the
expression ratio of antagonistic regulators, such as XIAP/
XAF1, play an important role in HCC and patient's prog-
nosis. Survivin and Livin/ML-IAP overexpression in HCCs
imply that their mRNA levels could be used as markers of
cancer tissue. XIAP expression levels (both mRNA and
protein) did not show any significant difference in HCC
tissue compared to cirrhotic tissue. Nonetheless its immu-
noreactivity correlated to patient's prognosis. More
importantly, XIAP/XAF1 expression ratio could be related
with patients' survival.
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